Search Results


Wed, Nov 11, 2009		3rd Annual Stability Testing Conference - Conference (BSG House, London, UK) Well planned, executed and managed stability studies are critical for understanding data generated during clinical trials. Stability testing is an expensive part of product development, but conducted efficiently, it can save money in latter parts of the lifecycle. Visiongain's 3rd Annual Stability Testing conference will examine developments in technology for stability assessment. As part of this 2-day event, leading authorities will assess the application and limitations of various analytical and statistical methods, as well as study design. Participants will be provided with a reliable evaluation of the principles and techniques associated with the stability testing of biologics and new pharmaceutical products.
Wed, Nov 11, 2009		Pre-Conference Seminar QbD IN INHALATION PRODUCT DEVELOPMENT - Course / Training / Workshop (The Cavendish Hotel, London) Full Details will follow shortly. Please contact andrea.james@management-forum.co.uk for further information or a brochure.
Wed, Nov 11, 2009		PHARMACEUTICAL REGULATORY AFFAIRS IN CHINA - Course / Training / Workshop (The Rembrandt Hotel, London) This seminar will provide an up-to-date coverage of all aspects playing an important role in gaining and maintaining a successful marketing authorisation for R&D based pharmaceutical products in PR China. In this carefully balanced programme, speakers will cover the underlying official regulatory sources and share the interpretation and practical aspects of putting these into practice in a day-to-day scenario. This seminar will also include an overview of the requirements for local manufacturing as well as of the patent situation and the current legal framework for pharmaceutical patents in PR China. An interactive session has been incorporated into the programme where participants will be invited to put learning into practice through the resolution of a case study. It is anticipated that this seminar will be useful both as an introductory course and as a refresher course to people who need to have an up-to-date and wide knowledge of the subject area.
Thu, Nov 12, 2009		3rd Annual Stability Testing Conference - Conference (BSG House, London, UK) Well planned, executed and managed stability studies are critical for understanding data generated during clinical trials. Stability testing is an expensive part of product development, but conducted efficiently, it can save money in latter parts of the lifecycle. Visiongain's 3rd Annual Stability Testing conference will examine developments in technology for stability assessment. As part of this 2-day event, leading authorities will assess the application and limitations of various analytical and statistical methods, as well as study design. Participants will be provided with a reliable evaluation of the principles and techniques associated with the stability testing of biologics and new pharmaceutical products.
Thu, Nov 12, 2009		PHARMACEUTICAL REGULATORY AFFAIRS IN CHINA - Course / Training / Workshop (The Rembrandt Hotel, London) This seminar will provide an up-to-date coverage of all aspects playing an important role in gaining and maintaining a successful marketing authorisation for R&D based pharmaceutical products in PR China. In this carefully balanced programme, speakers will cover the underlying official regulatory sources and share the interpretation and practical aspects of putting these into practice in a day-to-day scenario. This seminar will also include an overview of the requirements for local manufacturing as well as of the patent situation and the current legal framework for pharmaceutical patents in PR China. An interactive session has been incorporated into the programme where participants will be invited to put learning into practice through the resolution of a case study. It is anticipated that this seminar will be useful both as an introductory course and as a refresher course to people who need to have an up-to-date and wide knowledge of the subject area.
Wed, Nov 18, 2009		Practical Guide for Pharmacovigilance: Clinical Trials and Post Marketing - Course / Training / Workshop (SAS Radisson Hotel Boulogne) This is a basic overview course, intended for individuals who have limited experience in pharmacovigilance/drug safety monitoring. The focus will be on pharmacovigilance with traditional medicinal products, both investigational and marketed, intended for human use in clinical trials, in post marketing studies, and in the healthcare setting following product launch.
Thu, Nov 19, 2009		Practical Guide for Pharmacovigilance: Clinical Trials and Post Marketing - Course / Training / Workshop (SAS Radisson Hotel Boulogne) This is a basic overview course, intended for individuals who have limited experience in pharmacovigilance/drug safety monitoring. The focus will be on pharmacovigilance with traditional medicinal products, both investigational and marketed, intended for human use in clinical trials, in post marketing studies, and in the healthcare setting following product launch.
Thu, Nov 19, 2009		European Regulatory Affairs - Course / Training / Workshop (SAS Radisson Hotel Boulogne) This training course will provide an excellent introduction to the European Regulatory Procedures for personnel in regulatory affairs, clinical research, project management and other disciplines involved in the development of medicinal products. The course will cover the evolution of the Registration Systems available for approval of products since January 1995 in the European Union, together with major changes in New Medicines Legislation. Title IV of Regulation EC726/2004 on the European Medicines Agency -Responsibilities and Administrative Structure, came into effect on May 20, 2004. The remainder of the Regulation and all of Directive 2004/27/EC became effective in November 20, 2005. The very important changes in New Medicine Legislation concerning regulatory procedures, access to Centralised and Mutual Recognition Procedures, reduction in Regulatory Data protection will be described in detail. Detailed review will be offered on the changed Centralised and Mutual Recognition Procedures and New Decentralised Procedure with discussion of practical examples of product types suitable for each procedure. Other issues that impact on successful regulatory strategy in Europe, Harmonisation of Summary of Product Characteristics, Article 30 and Article 31 referrals and Supplementary Protection Certificate for Patents will be described. Also reviewed and discussed is the legal status of medicinal products and the procedure for switching from prescription only sale to OTC sale, legislation controlling Medical Devices and the Clinical Trial Directive. The workshop will provide strategic advice on how to file applications for the marketing authorisations in the European Union for staff involved in Regulatory Affairs. Regulatory strategy which impacts on commercial, business and licensing arrangements will be of importance to those responsible for business development.
Thu, Nov 19, 2009		Effective Risk-Based Applications of Drug cGMPs and Validation Requirements for Cosmetics and OTC Drug Products - Course / Training / Workshop (Malvern, PA)
Fri, Nov 20, 2009		Practical Guide for Pharmacovigilance: Clinical Trials and Post Marketing - Course / Training / Workshop (SAS Radisson Hotel Boulogne) This is a basic overview course, intended for individuals who have limited experience in pharmacovigilance/drug safety monitoring. The focus will be on pharmacovigilance with traditional medicinal products, both investigational and marketed, intended for human use in clinical trials, in post marketing studies, and in the healthcare setting following product launch.
Fri, Nov 20, 2009		European Regulatory Affairs - Course / Training / Workshop (SAS Radisson Hotel Boulogne) This training course will provide an excellent introduction to the European Regulatory Procedures for personnel in regulatory affairs, clinical research, project management and other disciplines involved in the development of medicinal products. The course will cover the evolution of the Registration Systems available for approval of products since January 1995 in the European Union, together with major changes in New Medicines Legislation. Title IV of Regulation EC726/2004 on the European Medicines Agency -Responsibilities and Administrative Structure, came into effect on May 20, 2004. The remainder of the Regulation and all of Directive 2004/27/EC became effective in November 20, 2005. The very important changes in New Medicine Legislation concerning regulatory procedures, access to Centralised and Mutual Recognition Procedures, reduction in Regulatory Data protection will be described in detail. Detailed review will be offered on the changed Centralised and Mutual Recognition Procedures and New Decentralised Procedure with discussion of practical examples of product types suitable for each procedure. Other issues that impact on successful regulatory strategy in Europe, Harmonisation of Summary of Product Characteristics, Article 30 and Article 31 referrals and Supplementary Protection Certificate for Patents will be described. Also reviewed and discussed is the legal status of medicinal products and the procedure for switching from prescription only sale to OTC sale, legislation controlling Medical Devices and the Clinical Trial Directive. The workshop will provide strategic advice on how to file applications for the marketing authorisations in the European Union for staff involved in Regulatory Affairs. Regulatory strategy which impacts on commercial, business and licensing arrangements will be of importance to those responsible for business development.
Fri, Nov 20, 2009		Effective Risk-Based Applications of Drug cGMPs and Validation Requirements for Cosmetics and OTC Drug Products - Course / Training / Workshop (Malvern, PA)
Mon, Nov 23, 2009		BIOLOGICAL EVALUATION OF MEDICAL DEVICES - Understand The New Approach To Biological Evaluation And Its Practical Application - Conference (Harrington Hall Hotel, London) The ISO 10993 series of standards, covering biological evaluation of medical devices, are well established and regulatory authorities worldwide expect compliance. In Europe compliance with the EN ISO 10993 standards is the easiest way to meet the essential product safety requirements of the Medical Device Directive. Several new parts in the series have been developed which promote a new philosophy of biological evaluation particularly parts 1, 2, 17 and 18. In addition, a major revision of ISO 10993-1 is near completion (FDIS) which incorporates a risk management approach and better co-ordinate the full set of the existing 20 parts in the series. This interactive seminar will provide practical opportunities for the application of these standards and the new approach to biological evaluation.
Tue, Nov 24, 2009		SUPPLIER QUALITY MANAGEMENT - How well do you know your Suppliers and Supply Chain? - Course / Training / Workshop (The Rembrandt Hotel, London) Topics to be Covered: Cost Effectiveness: The current trend is to source raw materials and APIs from outside Europe and the US, Supplies are more often sourced from India and China. Significant Challenges: Identification, Assessment, Approval, Management of the Supply Chain. The Regulatory Authorities: Close attention to how you manage your Supply Chain. The Impact on your Company: The impact of the increased attention from the Regulatory Authorities is felt both on large Pharma companies and smaller Generic manufacturers where the number of product lines present a daunting task if the supply chain is to be effectively managed
Tue, Nov 24, 2009		BIOLOGICAL EVALUATION OF MEDICAL DEVICES - Understand The New Approach To Biological Evaluation And Its Practical Application - Conference (Harrington Hall Hotel, London) The ISO 10993 series of standards, covering biological evaluation of medical devices, are well established and regulatory authorities worldwide expect compliance. In Europe compliance with the EN ISO 10993 standards is the easiest way to meet the essential product safety requirements of the Medical Device Directive. Several new parts in the series have been developed which promote a new philosophy of biological evaluation particularly parts 1, 2, 17 and 18. In addition, a major revision of ISO 10993-1 is near completion (FDIS) which incorporates a risk management approach and better co-ordinate the full set of the existing 20 parts in the series. This interactive seminar will provide practical opportunities for the application of these standards and the new approach to biological evaluation.
Tue, Nov 24, 2009 9:00am		Small Scale Bio-production: Beyond the Flask. - Conference (BioPark Hertfordshire, Welwyn Garden City) "Once you can produce it in a flask, what next? The focus of this meeting will be on techniques for the bioproduction of usable quantities of biologic materials, specifically recombinant proteins, monoclonal antibodies, cytokines viruses and other secreted cellular products from eukaryotic cells. Topics covered will include expression systems, mammalian vs. insect vs. other, constituitive vs. transient expression, cell culture medium considerations and culture devices for scale-up that can be used in any laboratory. This meeting should show the fastest pathway from discovery to proof of principle and the production of 100 mgs to several grams of product" Meeting Chair: Dr John J.S. Cadwell, President and CEO, FiberCell Systems Inc, USA
Mon, Nov 30, 2009		Active Pharmaceutical Ingredient (API) and Drug Product Specifications - Course / Training / Workshop (Malvern, PA)
Tue, Dec 1, 2009		Active Pharmaceutical Ingredient (API) and Drug Product Specifications - Course / Training / Workshop (Malvern, PA)
Wed, Dec 2, 2009		Pharma partnering event PharmaVenue - Conference (AB Skipper Hotel Barcelona (Spain)) PharmaVenue offers an unparalleled opportunity to identify new business opportunities and meet decision makers to forge new partnerships in the field of * Innovations, * Generics and * OTC/Healthcare products PharmaVenue can help your business get to the next level through quality one-to-one meetings with senior level executives. Our state-of-the art interactive partnering software enables you to efficiently select the most attractive license opportunities, pre-arrange and conduct many productive business meetings to unlock future revenue streams. * By having access to detailed information on key license projects of each participating company prior to the event and with help of several new interactive networking tools we facilitate the process of screening potential opportunities and partners. * During six weeks, you may easily submit and review meeting requests through the password protected web-site. You will have access to your individual meeting schedule one week prior to the event and may make your final adjustments to your agenda. Our sophisticated software pre-schedules more than 95%* of all meeting requests. * Experience more productive business meetings in two days than in the entire rest of the year.
Wed, Dec 2, 2009		Active Pharmaceutical Ingredient (API) and Drug Product Specifications - Course / Training / Workshop (Malvern, PA)
Thu, Dec 3, 2009		Pharma partnering event PharmaVenue - Conference (AB Skipper Hotel Barcelona (Spain)) PharmaVenue offers an unparalleled opportunity to identify new business opportunities and meet decision makers to forge new partnerships in the field of * Innovations, * Generics and * OTC/Healthcare products PharmaVenue can help your business get to the next level through quality one-to-one meetings with senior level executives. Our state-of-the art interactive partnering software enables you to efficiently select the most attractive license opportunities, pre-arrange and conduct many productive business meetings to unlock future revenue streams. * By having access to detailed information on key license projects of each participating company prior to the event and with help of several new interactive networking tools we facilitate the process of screening potential opportunities and partners. * During six weeks, you may easily submit and review meeting requests through the password protected web-site. You will have access to your individual meeting schedule one week prior to the event and may make your final adjustments to your agenda. Our sophisticated software pre-schedules more than 95%* of all meeting requests. * Experience more productive business meetings in two days than in the entire rest of the year.
Thu, Dec 3, 2009		Dermatological Advances 2009 Conference - Conference (BSG House, London, UK) Dermatology is one of the most promising sectors within the global pharmaceutical market. It has witnessed remarkable sales revenues of over $18bn in 2007, and will expand significantly in the next 10 years. Skin infections and disorders such as acne, psoriasis and dermatitis remain major revenue generators for the pharmaceutical and biotech companies. The dermatology market will regain 3.5% growth by 2010, with the development of anti-psoriasis, acne and dermatitis products and treatments (Source: visiongain). Our conference will focus on the advances and innovations in novel drug delivery, therapeutic skin treatments and anti-ageing products, primarily in the developing countries.
Thu, Dec 3, 2009		RISK MANAGEMENT - Applying it and meeting the Challenges for Industry - Course / Training / Workshop (Harrington Hall Hotel, London) INTRODUCTION Risk management is a complex operation involving the identification of risk, the assessment of that risk against a target and subsequent reduction or mitigation of the risk to bring it into the realms of acceptability. Within the Pharmaceutical / Biopharmaceutical industry we work with pharmaceutically active materials which are often potentially hazardous to both the patient and to our production operators. As an industry we need to take a holistic approach to controlling these risks. We manage the risks so that we can in a timely manner bring safe, effective medicines to the patient and at the same time do not expose our operators and support staff to health hazards. We need to take a lifecycle approach to risk management from product development through commercial supply. In doing so it is necessary to recognise that whilst the hazard is fixed, the risk can vary. A number of standard tools are available for risk management. Which ones should you use and when? ICH Q9 has recently been incorporated into the GMP for EU, Japan and USA. It is stated to be non-mandatory, but what does this mean in practice. What changes has ICH Q9 brought about for you / your company / your dealings with the regulators? WHO SHOULD ATTEND This seminar will be of particular interest to all personnel who are or will become involved in any of the following pharmaceutical manufacturing activities: ■ Manufacture or QA of API or drug product ■ Manufacturing rationalisation ■ Site transfer for API and / or drug product ■ GMP compliance ■ Management of regulatory QA / manufacturing QA interfaces ■ Design and construction of manufacturing facilities / processes ■ Validation / Cleaning validation ■ Auditing of own company or supplier Personnel from the following backgrounds: ■ Production ■ Quality Assurance ■ Engineering ■ Regulatory Affairs Compliance ■ Project Planners
Fri, Dec 4, 2009		Dermatological Advances 2009 Conference - Conference (BSG House, London, UK) Dermatology is one of the most promising sectors within the global pharmaceutical market. It has witnessed remarkable sales revenues of over $18bn in 2007, and will expand significantly in the next 10 years. Skin infections and disorders such as acne, psoriasis and dermatitis remain major revenue generators for the pharmaceutical and biotech companies. The dermatology market will regain 3.5% growth by 2010, with the development of anti-psoriasis, acne and dermatitis products and treatments (Source: visiongain). Our conference will focus on the advances and innovations in novel drug delivery, therapeutic skin treatments and anti-ageing products, primarily in the developing countries.
Fri, Dec 4, 2009		THE EU COSMETICS DIRECTIVE AND THE NEW COSMETICS REGULATIONS - Course / Training / Workshop (The Rembrandt Hotel, London) A quick examination of the cosmetic products sold in many European shops will pick up a significant number of products that do not comply with the EU Cosmetic Regulations. This demonstrates that there are many companies who do not understand the requirements. The EU has recently stated that they wish to enforce labelling requirements more vigorously and there are heavy fines for infringements. It is easy for the authorities to walk round any shop selling cosmetics and look at the labels. Even a minor infringement could lead to a time consuming investigation. Although very complex and lengthy, the regulations are actually quite straightforward if they are summarised, explained properly and put into context. The object of this seminar is to do just this in thorough but simple terms. You will learn what the EU Cosmetics Directive is, how to understand and comply with it.
Fri, Dec 4, 2009		RISK MANAGEMENT - Applying it and meeting the Challenges for Industry - Course / Training / Workshop (Harrington Hall Hotel, London) INTRODUCTION Risk management is a complex operation involving the identification of risk, the assessment of that risk against a target and subsequent reduction or mitigation of the risk to bring it into the realms of acceptability. Within the Pharmaceutical / Biopharmaceutical industry we work with pharmaceutically active materials which are often potentially hazardous to both the patient and to our production operators. As an industry we need to take a holistic approach to controlling these risks. We manage the risks so that we can in a timely manner bring safe, effective medicines to the patient and at the same time do not expose our operators and support staff to health hazards. We need to take a lifecycle approach to risk management from product development through commercial supply. In doing so it is necessary to recognise that whilst the hazard is fixed, the risk can vary. A number of standard tools are available for risk management. Which ones should you use and when? ICH Q9 has recently been incorporated into the GMP for EU, Japan and USA. It is stated to be non-mandatory, but what does this mean in practice. What changes has ICH Q9 brought about for you / your company / your dealings with the regulators? WHO SHOULD ATTEND This seminar will be of particular interest to all personnel who are or will become involved in any of the following pharmaceutical manufacturing activities: ■ Manufacture or QA of API or drug product ■ Manufacturing rationalisation ■ Site transfer for API and / or drug product ■ GMP compliance ■ Management of regulatory QA / manufacturing QA interfaces ■ Design and construction of manufacturing facilities / processes ■ Validation / Cleaning validation ■ Auditing of own company or supplier Personnel from the following backgrounds: ■ Production ■ Quality Assurance ■ Engineering ■ Regulatory Affairs Compliance ■ Project Planners
Mon, Dec 7, 2009		Stability Programs for Product Shelf Life - From Development to Approval - Course / Training / Workshop (Malvern, PA)
Tue, Dec 8, 2009		Stability Programs for Product Shelf Life - From Development to Approval - Course / Training / Workshop (Malvern, PA)
Mon, Jan 18, 2010		FDA APPROVAL PROCESS FOR MEDICAL DEVICES - Course / Training / Workshop (The Rembrandt Hotel, London) This seminar will highlight new changes in the medical device regulations and provide an overview of the submission of documents to the FDA for approval of medical device products. Participants will gain a better understanding of the medical device approval process and the underlying scientific and regulatory principles involved. Guidelines for each aspect of research will be provided, as well as information on the structuring of submissions and post-approval documents. Information on maintaining ongoing relationships with the FDA will also be discussed. Attendance at this seminar will enable delegates to provide the FDA with the necessary information to obtain product approval. Upon completion of this seminar, participants will: Understand the FDA medical device approval system, Know what is required for an Investigational Device Exemption (IDE), Learn the contents of a Post-Market Approval (PMA), Discover what to include in an annual report
Tue, Jan 19, 2010		FDA APPROVAL PROCESS FOR MEDICAL DEVICES - Course / Training / Workshop (The Rembrandt Hotel, London) This seminar will highlight new changes in the medical device regulations and provide an overview of the submission of documents to the FDA for approval of medical device products. Participants will gain a better understanding of the medical device approval process and the underlying scientific and regulatory principles involved. Guidelines for each aspect of research will be provided, as well as information on the structuring of submissions and post-approval documents. Information on maintaining ongoing relationships with the FDA will also be discussed. Attendance at this seminar will enable delegates to provide the FDA with the necessary information to obtain product approval. Upon completion of this seminar, participants will: Understand the FDA medical device approval system, Know what is required for an Investigational Device Exemption (IDE), Learn the contents of a Post-Market Approval (PMA), Discover what to include in an annual report
Tue, Jan 19, 2010		PHARMACEUTICAL REGULATORY AFFAIRS IN ASIA INCLUDING INDIA - Course / Training / Workshop (The Rembrandt Hotel, London) This seminar will focus on R&D based pharmaceutical products in Asia and will provide you with: A carefully balanced programme, Up-to-date coverage, All important aspects of gaining and maintaining a successful Marketing Authorisation in Asia, Coverage of underlying official regulatory sources, An interpretation of practical aspects, An overview of the requirements for local manufacturing, Recent Developments, Harmonisation Initiatives, The opportunity to exchange experiences with other delegates
Wed, Jan 20, 2010		PHARMACEUTICAL REGULATORY AFFAIRS IN ASIA INCLUDING INDIA - Course / Training / Workshop (The Rembrandt Hotel, London) This seminar will focus on R&D based pharmaceutical products in Asia and will provide you with: A carefully balanced programme, Up-to-date coverage, All important aspects of gaining and maintaining a successful Marketing Authorisation in Asia, Coverage of underlying official regulatory sources, An interpretation of practical aspects, An overview of the requirements for local manufacturing, Recent Developments, Harmonisation Initiatives, The opportunity to exchange experiences with other delegates
Wed, Jan 20, 2010		EC MEDICAL DEVICES VIGILANCE SYSTEM AND POST MARKETING SURVEILLANCE - Course / Training / Workshop (The Cavendish Hotel, London) WHO SHOULD ATTEND This conference will be of importance to all those involved in the Medical Device Industry in the following departments; Manufacturing, Research and Development, Registration, Product Safety, Adverse Event Monitoring, Regulatory Affairs, Distribution and all those interested in Medical Device Vigilance in the European Community. PREPARATION It is advisable to read the EC Medical Device Vigilance Guidelines prior to attending this conference. Chairman: Roland Gérard - Vice President Governmental Affairs and RegulatoryCompliance - Europe, Middle East, Africa and Canada - St Jude Medical With a Panel of Key European Experts, including representatives from Competent Authorities, Notified Bodies and Industry BENEFITS IN ATTENDING: ■ Understand the EU Vigilance Process ■ Realise the Legal Obligations ■ Know How to Handle Field Safety Corrective Actions (FSCAs) ■ Discover What a Notified Body Expects from an Audit on PMS Systems ■ Discuss Risk Management ■ Hear How Various Member States Handle Vigilance Reports ■ Clarify the Role of Notified Bodies in Vigilance and FSCAs ■ Gain a Better Understanding of Adverse Incident Reporting during Clinical Studies
Thu, Jan 21, 2010		EC MEDICAL DEVICES VIGILANCE SYSTEM AND POST MARKETING SURVEILLANCE - Course / Training / Workshop (The Cavendish Hotel, London) WHO SHOULD ATTEND This conference will be of importance to all those involved in the Medical Device Industry in the following departments; Manufacturing, Research and Development, Registration, Product Safety, Adverse Event Monitoring, Regulatory Affairs, Distribution and all those interested in Medical Device Vigilance in the European Community. PREPARATION It is advisable to read the EC Medical Device Vigilance Guidelines prior to attending this conference. Chairman: Roland Gérard - Vice President Governmental Affairs and RegulatoryCompliance - Europe, Middle East, Africa and Canada - St Jude Medical With a Panel of Key European Experts, including representatives from Competent Authorities, Notified Bodies and Industry BENEFITS IN ATTENDING: ■ Understand the EU Vigilance Process ■ Realise the Legal Obligations ■ Know How to Handle Field Safety Corrective Actions (FSCAs) ■ Discover What a Notified Body Expects from an Audit on PMS Systems ■ Discuss Risk Management ■ Hear How Various Member States Handle Vigilance Reports ■ Clarify the Role of Notified Bodies in Vigilance and FSCAs ■ Gain a Better Understanding of Adverse Incident Reporting during Clinical Studies
Tue, Jan 26, 2010 8:55am		World Drug Delivery and Formulation 2010 - Conference (Radisson BLU Scandinavia Hotel, Dusseldorf, Germany) 26-27th January 2010 Radisson BLU Scandinavia Hotel, Dusseldorf, Germany With increasing generic competition, challenging molecules coming through discovery and continual pressure to produce cost-effective drugs, companies are increasingly turning to formulation and delivery to secure the success of current and new drug products. World Drug Delivery and Formulation 2010 is the event this year for both scientific and business leaders working in formulation and delivery to debate the challenges affecting them. This multi stream delivery and formulation event will focus on both scientific and business issues. This will give everyone the perfect opportunity to attend sessions dedicated to their main area of interest, whilst networking with scientific and business peers from across the entire formulation and delivery spectrum.
Wed, Jan 27, 2010 8:55am		World Drug Delivery and Formulation 2010 - Conference (Radisson BLU Scandinavia Hotel, Dusseldorf, Germany) 26-27th January 2010 Radisson BLU Scandinavia Hotel, Dusseldorf, Germany With increasing generic competition, challenging molecules coming through discovery and continual pressure to produce cost-effective drugs, companies are increasingly turning to formulation and delivery to secure the success of current and new drug products. World Drug Delivery and Formulation 2010 is the event this year for both scientific and business leaders working in formulation and delivery to debate the challenges affecting them. This multi stream delivery and formulation event will focus on both scientific and business issues. This will give everyone the perfect opportunity to attend sessions dedicated to their main area of interest, whilst networking with scientific and business peers from across the entire formulation and delivery spectrum.
Wed, Feb 10, 2010		5th Annual Drug Delivery Systems Conference - Conference (BSG House, London, UK) Drug delivery continues to be increasingly important sector in the pharmaceutical industry and has undergone rapid growth in the last few years. Drug delivery technologies are driving growth of pharmaceutical companies and boosting their revenue by extending the product profitable lifecycle through new formulations, combinations and repositioning. The predominant focus of this conference will be in advancements being made in the drug delivery technologies and understanding the regulatory and legal issues faced by the them.
Thu, Feb 11, 2010		5th Annual Drug Delivery Systems Conference - Conference (BSG House, London, UK) Drug delivery continues to be increasingly important sector in the pharmaceutical industry and has undergone rapid growth in the last few years. Drug delivery technologies are driving growth of pharmaceutical companies and boosting their revenue by extending the product profitable lifecycle through new formulations, combinations and repositioning. The predominant focus of this conference will be in advancements being made in the drug delivery technologies and understanding the regulatory and legal issues faced by the them.
Fri, Mar 12, 2010		Recombinant vaccines - right molecule, right place, right time? - Conference (The BioPark, Hertfordshire, UK) "Huge technological advances have been made recently in the genomic and post-genomic analyses of pathogens and disease. To exploit these advances for the production of successful recombinant vaccines we need strategies to select appropriate molecules and to deliver them appropriately to stimulate protective immune responses. This meeting will explore both candidate discovery and the tools for delivering vaccines effectively". Meeting Chair: Dr Alasdair Nisbet, Moredun Research Institute, UK. The meeting has CPD approval.
Tue, Mar 16, 2010		Pharma & Biotech Supply Chain Asia 2010 - Conference (Raffles City Convention Centre, Singapore) Pharma & Biotech Supply Chain Asia 2010 brings together pharmaceutical and biotech manufacturers, clinical researchers, distributors and solution providers to address how the industry can collaborate to further strengthen their supply chain in challenging economic conditions to achieve cost optimization, patient safety, product integrity and security in Asia.
Wed, Mar 17, 2010		Pharma & Biotech Supply Chain Asia 2010 - Conference (Raffles City Convention Centre, Singapore) Pharma & Biotech Supply Chain Asia 2010 brings together pharmaceutical and biotech manufacturers, clinical researchers, distributors and solution providers to address how the industry can collaborate to further strengthen their supply chain in challenging economic conditions to achieve cost optimization, patient safety, product integrity and security in Asia.
Thu, Mar 18, 2010		Pharma & Biotech Supply Chain Asia 2010 - Conference (Raffles City Convention Centre, Singapore) Pharma & Biotech Supply Chain Asia 2010 brings together pharmaceutical and biotech manufacturers, clinical researchers, distributors and solution providers to address how the industry can collaborate to further strengthen their supply chain in challenging economic conditions to achieve cost optimization, patient safety, product integrity and security in Asia.
Fri, Mar 19, 2010		Pharma & Biotech Supply Chain Asia 2010 - Conference (Raffles City Convention Centre, Singapore) Pharma & Biotech Supply Chain Asia 2010 brings together pharmaceutical and biotech manufacturers, clinical researchers, distributors and solution providers to address how the industry can collaborate to further strengthen their supply chain in challenging economic conditions to achieve cost optimization, patient safety, product integrity and security in Asia.
Mon, Jun 7, 2010		Cardiovascular Clinical Trials in Emerging Markets 2010 - Conference (Prague, Czech Republic) The globalisation of clinical trials has meant that increasingly pharmaceutical and biotechnology companies are turning towards performing clinical trials in emerging markets such as Asia Pacific, Central and Eastern Europe, Latin America and the Middle east. Within these emerging markets, the ability to research new products can also provide a way to maximize its potential use in countries typically not considered for commercial viability. However cultural, ethical, logistical and regulatory challenges can prove to be the biggest roadblocks when conducting trials in emerging countries and this is particularly true when conducting cardiovascular clinical trials. The Congress will focus on the current results, problems and solutions of conducting cardiovascular clinical trials in key emerging markets as well as examining the challenges facing the pharmaceutical industry in pursuing a contemporary approach in the development of drugs and treatment in key areas.
Tue, Jun 8, 2010		Cardiovascular Clinical Trials in Emerging Markets 2010 - Conference (Prague, Czech Republic) The globalisation of clinical trials has meant that increasingly pharmaceutical and biotechnology companies are turning towards performing clinical trials in emerging markets such as Asia Pacific, Central and Eastern Europe, Latin America and the Middle east. Within these emerging markets, the ability to research new products can also provide a way to maximize its potential use in countries typically not considered for commercial viability. However cultural, ethical, logistical and regulatory challenges can prove to be the biggest roadblocks when conducting trials in emerging countries and this is particularly true when conducting cardiovascular clinical trials. The Congress will focus on the current results, problems and solutions of conducting cardiovascular clinical trials in key emerging markets as well as examining the challenges facing the pharmaceutical industry in pursuing a contemporary approach in the development of drugs and treatment in key areas.
Thu, Oct 7, 2010		Induced pluripotent stem cells: production and utility in regenerative medicine - Conference (BioPark Hertfordshire , Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX ,United Kingdom) Gene delivery technology and iPS cell characterization and subsequent cell differentiation are critical aspects of iPS cell biology. This meeting will address both issues.

powered by VTCalendar 2.2.1

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.